I totally agree with penniestodimes. The number of CYDY shareholders is relatively small. I wish we uplisted a few years ago.
As long as we stay on this crappy OTC market with no analyst coverage, we will not really go anywhere fast with our share price.
Can't wait for the uplist to a REAL exchange with analyst coverage and institutional buying. Though nervous about shorting that may occur after the uplist.
The real bump in price will come if FDA approves PRO 140. It would be wise of management to up list close to an anticipated FDA decision, unless a BO comes before hand.